methylphenidate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1767 113-45-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • methylphenidate
  • calocain
  • methylphenidan
  • phenidylate
  • methylphenidate hydrochloride
  • concerta
  • methylphenidate HCl
A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
  • Molecular weight: 233.31
  • Formula: C14H19NO2
  • CLOGP: 2.56
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 38.33
  • ALOGS: -3.11
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.29 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 22 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.42 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.85 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 5, 1955 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicidal ideation 287.47 10.90 272 33243 56110 46596437
Product quality issue 229.06 10.90 196 33319 35452 46617095
Agitation 186.31 10.90 214 33301 55201 46597346
Anxiety 186.18 10.90 406 33109 181551 46470996
Product substitution issue 177.62 10.90 119 33396 14912 46637635
Depression 166.56 10.90 373 33142 169731 46482816
Aggression 158.31 10.90 131 33384 22613 46629934
Tachycardia 156.81 10.90 267 33248 99355 46553192
Disturbance in attention 145.19 10.90 144 33371 31416 46621131
No adverse event 137.17 10.90 145 33370 34086 46618461
Abnormal behaviour 131.59 10.90 114 33401 20944 46631603
Drug abuse 124.46 10.90 188 33327 63220 46589327
Attention deficit hyperactivity disorder 121.53 10.90 49 33466 2123 46650424
Tic 117.07 10.90 41 33474 1195 46651352
Precocious puberty 112.11 10.90 27 33488 192 46652355
Irritability 111.35 10.90 120 33395 28826 46623721
Cataplexy 107.94 10.90 38 33477 1125 46651422
Intentional overdose 107.35 10.90 178 33337 64766 46587781
Mydriasis 95.51 10.90 71 33444 10482 46642065
Rheumatoid arthritis 92.05 10.90 29 33486 240186 46412361
Suicide attempt 91.15 10.90 151 33364 54885 46597662
Application site erythema 86.22 10.90 50 33465 4854 46647693
Hallucination, auditory 85.54 10.90 67 33448 10689 46641858
Pre-existing condition improved 84.53 10.90 55 33460 6557 46645990
Psychotic disorder 78.73 10.90 89 33426 22532 46630015
Tremor 76.73 10.90 219 33296 115420 46537127
Intentional self-injury 75.60 10.90 90 33425 24076 46628471
Wrong technique in product usage process 70.36 10.90 134 33381 54288 46598259
Apathy 68.25 10.90 50 33465 7218 46645329
Product administered at inappropriate site 66.39 10.90 33 33482 2350 46650197
Therapeutic response unexpected 64.04 10.90 67 33448 15549 46636998
Overdose 63.66 10.90 189 33326 101790 46550757
Toxicity to various agents 63.29 10.90 310 33205 211456 46441091
Rapid eye movement sleep behaviour disorder 62.62 10.90 16 33499 149 46652398
Acute kidney injury 62.30 10.90 47 33468 235808 46416739
Application site irritation 62.23 10.90 29 33486 1790 46650757
Psychomotor hyperactivity 59.95 10.90 52 33463 9561 46642986
Obsessive-compulsive disorder 59.78 10.90 34 33481 3181 46649366
Diarrhoea 58.05 10.90 207 33308 559395 46093152
Insomnia 57.02 10.90 252 33263 164672 46487875
Somnambulism 55.02 10.90 38 33477 4999 46647548
Bruxism 53.68 10.90 31 33484 2986 46649561
Anaemia 53.44 10.90 63 33452 255716 46396831
Hallucination 52.65 10.90 113 33402 49838 46602709
Enuresis 50.75 10.90 26 33489 1974 46650573
Feeling abnormal 50.16 10.90 200 33315 124860 46527687
Product administration error 49.91 10.90 66 33449 19615 46632932
Educational problem 49.73 10.90 15 33500 268 46652279
Drug dependence 49.33 10.90 66 33449 19835 46632712
Dystonia 49.23 10.90 50 33465 11207 46641340
Product colour issue 48.19 10.90 18 33497 633 46651914
Sleep apnoea syndrome 46.63 10.90 68 33447 22133 46630414
Impulsive behaviour 45.25 10.90 22 33493 1493 46651054
Social anxiety disorder 45.04 10.90 15 33500 374 46652173
Muscle twitching 44.82 10.90 54 33461 14618 46637929
Growth retardation 44.81 10.90 19 33496 936 46651611
Neutropenia 43.98 10.90 24 33491 143180 46509367
Joint swelling 42.67 10.90 34 33481 166039 46486508
Somnolence 42.40 10.90 223 33292 156298 46496249
Muscle contracture 41.56 10.90 20 33495 1327 46651220
Bipolar disorder 41.11 10.90 37 33478 7140 46645407
Panic attack 41.07 10.90 61 33454 20181 46632366
Febrile neutropenia 40.79 10.90 9 33506 94618 46557929
Parasomnia 40.20 10.90 14 33501 401 46652146
Drug diversion 39.97 10.90 17 33498 844 46651703
Pulmonary malformation 38.96 10.90 10 33505 95 46652452
Splenic infarction 38.63 10.90 20 33495 1552 46650995
Application site pruritus 38.57 10.90 28 33487 3985 46648562
Headache 38.38 10.90 517 32998 477835 46174712
Contraindicated product administered 37.88 10.90 6 33509 79941 46572606
Arthralgia 37.60 10.90 135 33380 364468 46288079
Intentional product misuse 36.97 10.90 95 33420 47033 46605514
Death 36.79 10.90 121 33394 335427 46317120
Haemoglobin decreased 36.24 10.90 24 33491 128925 46523622
Affective disorder 36.15 10.90 29 33486 4786 46647761
Dyskinesia 34.66 10.90 69 33446 28856 46623691
Memory impairment 34.52 10.90 128 33387 77209 46575338
Dyspnoea 34.45 10.90 223 33292 515325 46137222
Hallucination, visual 33.62 10.90 52 33463 17821 46634726
Anger 33.58 10.90 42 33473 11810 46640737
Application site urticaria 33.54 10.90 11 33504 261 46652286
Depressed mood 33.53 10.90 74 33441 33245 46619302
Delusion of parasitosis 33.29 10.90 6 33509 6 46652541
Crying 32.32 10.90 56 33459 21085 46631462
Narcolepsy 32.14 10.90 16 33499 1143 46651404
Livedo reticularis 31.99 10.90 20 33495 2224 46650323
Exposure during pregnancy 31.95 10.90 158 33357 108054 46544493
Withdrawal syndrome 31.68 10.90 51 33464 18083 46634464
Respiratory tract malformation 31.65 10.90 8 33507 71 46652476
Feeling jittery 31.18 10.90 39 33476 10969 46641578
Sepsis 31.14 10.90 31 33484 135983 46516564
Multiple sclerosis relapse 31.08 10.90 83 33432 42042 46610505
Paranoia 30.74 10.90 38 33477 10559 46641988
Restlessness 30.72 10.90 61 33454 25463 46627084
Hyperventilation 30.17 10.90 28 33487 5619 46646928
Solar urticaria 29.95 10.90 7 33508 43 46652504
Pneumonia 29.80 10.90 154 33361 376166 46276381
Seizure 29.73 10.90 170 33345 122884 46529663
Emotional disorder 29.21 10.90 40 33475 12284 46640263
Completed suicide 29.20 10.90 192 33323 145728 46506819
Drug hypersensitivity 28.76 10.90 85 33430 243740 46408807
Heart rate increased 28.67 10.90 118 33397 74673 46577874
Lung cyst 28.54 10.90 8 33507 109 46652438
Mania 28.47 10.90 37 33478 10809 46641738
Cardiac failure 28.25 10.90 11 33504 79937 46572610
Infection 27.76 10.90 33 33482 133559 46518988
Negative thoughts 27.75 10.90 13 33502 812 46651735
Thrombocytopenia 27.68 10.90 30 33485 126551 46525996
Cardiac failure congestive 27.26 10.90 16 33499 91734 46560813
Meningitis streptococcal 26.68 10.90 8 33507 140 46652407
Amphetamines positive 26.59 10.90 7 33508 74 46652473
Pancytopenia 26.48 10.90 14 33501 85044 46567503
Wound infection fungal 26.42 10.90 7 33508 76 46652471
Euphoric mood 26.42 10.90 23 33492 4249 46648298
Snoring 26.41 10.90 21 33494 3421 46649126
Optic disc haemorrhage 25.79 10.90 6 33509 36 46652511
Serotonin syndrome 25.75 10.90 55 33460 24165 46628382
Interstitial lung disease 25.67 10.90 4 33511 53945 46598602
Swelling 25.61 10.90 31 33484 124480 46528067
Post-traumatic stress disorder 25.45 10.90 22 33493 4026 46648521
Pre-eclampsia 25.37 10.90 30 33485 7964 46644583
Hypersomnia 25.05 10.90 42 33473 15397 46637150
Tachyphrenia 24.91 10.90 14 33501 1280 46651267
Renal failure 24.75 10.90 27 33488 113567 46538980
Sleep-related eating disorder 24.75 10.90 11 33504 608 46651939
Mood altered 24.69 10.90 38 33477 12969 46639578
Peripheral swelling 24.24 10.90 48 33467 158023 46494524
Multiple organ dysfunction syndrome 24.23 10.90 4 33511 51706 46600841
Lower respiratory tract infection 24.23 10.90 5 33510 55084 46597463
Migraine 24.15 10.90 107 33408 69919 46582628
Gastrointestinal haemorrhage 23.69 10.90 13 33502 77360 46575187
Maternal exposure during breast feeding 23.54 10.90 18 33497 2771 46649776
Psychiatric symptom 23.45 10.90 22 33493 4475 46648072
Tachypnoea 23.23 10.90 39 33476 14312 46638235
Product prescribing error 23.03 10.90 47 33468 20000 46632547
Eosinophilic myocarditis 22.90 10.90 9 33506 364 46652183
Drug screen negative 22.67 10.90 9 33506 374 46652173
Perinatal depression 22.58 10.90 10 33505 548 46651999
Application site rash 22.53 10.90 17 33498 2565 46649982
Axonal neuropathy 22.49 10.90 12 33503 990 46651557
Septic shock 22.11 10.90 7 33508 57886 46594661
Product taste abnormal 21.89 10.90 15 33500 1948 46650599
Glossodynia 21.78 10.90 3 33512 44370 46608177
Chronic fatigue syndrome 21.74 10.90 12 33503 1059 46651488
Weight decreased 21.65 10.90 239 33276 210610 46441937
Logorrhoea 21.63 10.90 16 33499 2343 46650204
Hyperkalaemia 21.49 10.90 5 33510 50704 46601843
Open angle glaucoma 21.48 10.90 8 33507 279 46652268
Atrial fibrillation 21.08 10.90 26 33489 103564 46548983
Sleep paralysis 20.87 10.90 9 33506 462 46652085
Renal impairment 20.67 10.90 14 33501 74358 46578189
Burnout syndrome 20.46 10.90 7 33508 190 46652357
Protrusion tongue 20.21 10.90 8 33507 330 46652217
Infusion related reaction 19.97 10.90 26 33489 101182 46551365
Abnormal sleep-related event 19.80 10.90 10 33505 737 46651810
General physical health deterioration 19.67 10.90 33 33482 115736 46536811
Treatment failure 19.32 10.90 23 33492 93064 46559483
Application site discolouration 19.22 10.90 10 33505 784 46651763
Respiratory failure 19.08 10.90 24 33491 94792 46557755
Social avoidant behaviour 19.01 10.90 16 33499 2823 46649724
Pleural effusion 18.87 10.90 19 33496 82933 46569614
Trichotillomania 18.72 10.90 6 33509 132 46652415
Compulsive lip biting 18.72 10.90 3 33512 0 46652547
Bezoar 18.62 10.90 12 33503 1407 46651140
Mood swings 18.55 10.90 38 33477 16214 46636333
Learning disorder 18.37 10.90 8 33507 421 46652126
Incorrect product administration duration 18.20 10.90 28 33487 9549 46642998
Initial insomnia 18.07 10.90 19 33496 4433 46648114
Hypotension 17.91 10.90 96 33419 232493 46420054
Application site pain 17.83 10.90 18 33497 4005 46648542
Thinking abnormal 17.69 10.90 28 33487 9786 46642761
Sensory level abnormal 17.63 10.90 6 33509 160 46652387
Leukopenia 17.52 10.90 14 33501 68329 46584218
Nystagmus 17.45 10.90 21 33494 5678 46646869
Rash 17.33 10.90 168 33347 356344 46296203
Therapeutic response changed 16.98 10.90 9 33506 733 46651814
Cyanosis 16.67 10.90 36 33479 15935 46636612
Bisexuality 16.64 10.90 3 33512 3 46652544
Antiphospholipid syndrome 16.58 10.90 12 33503 1700 46650847
Hunger 16.56 10.90 17 33498 3858 46648689
Platelet count decreased 16.54 10.90 29 33486 99995 46552552
Delusion 16.27 10.90 29 33486 11159 46641388
Consciousness fluctuating 16.13 10.90 8 33507 567 46651980
Libido decreased 16.06 10.90 14 33501 2591 46649956
Affect lability 16.02 10.90 24 33491 7996 46644551
Systemic lupus erythematosus 15.91 10.90 14 33501 65166 46587381
Product complaint 15.88 10.90 30 33485 12071 46640476
Nightmare 15.73 10.90 36 33479 16562 46635985
Psoriasis 15.70 10.90 20 33495 78584 46573963
Body temperature increased 15.41 10.90 46 33469 24815 46627732
Vasospasm 15.37 10.90 8 33507 628 46651919
Hyponatraemia 15.33 10.90 31 33484 101301 46551246
Cough 15.10 10.90 100 33415 230149 46422398
Substance use 15.08 10.90 7 33508 428 46652119
Lactic acidosis 15.07 10.90 3 33512 33906 46618641
C-reactive protein increased 15.02 10.90 12 33503 58578 46593969
Mobility decreased 14.81 10.90 13 33502 60581 46591966
Hepatic failure 14.76 10.90 3 33512 33413 46619134
Raynaud's phenomenon 14.65 10.90 10 33505 1290 46651257
Seizure like phenomena 14.52 10.90 9 33506 986 46651561
Arthropathy 14.51 10.90 24 33491 84676 46567871
Rhabdomyolysis 14.42 10.90 6 33509 41903 46610644
Blister 14.40 10.90 7 33508 44624 46607923
Mucosal inflammation 14.38 10.90 5 33510 38971 46613576
Pyrexia 14.28 10.90 171 33344 348631 46303916
Palpitations 14.25 10.90 117 33398 95142 46557405
International normalised ratio increased 14.17 10.90 8 33507 46875 46605672
Polycystic ovaries 14.09 10.90 10 33505 1374 46651173
Decreased appetite 14.04 10.90 206 33309 193630 46458917
Rectal haemorrhage 13.95 10.90 5 33510 38250 46614297
Sedation 13.83 10.90 42 33473 22868 46629679
Distractibility 13.82 10.90 6 33509 313 46652234
Acne 13.45 10.90 38 33477 19881 46632666
Phobia 13.41 10.90 6 33509 337 46652210
Regressive behaviour 13.39 10.90 4 33511 69 46652478
Illness 13.27 10.90 28 33487 12196 46640351
Brain death 13.19 10.90 13 33502 2810 46649737
Cleft lip and palate 13.07 10.90 6 33509 358 46652189
Coronary artery disease 13.03 10.90 4 33511 33748 46618799
Foot fracture 12.87 10.90 37 33478 19545 46633002
Herpes zoster 12.81 10.90 18 33497 67854 46584693
Formication 12.81 10.90 15 33500 3941 46648606
Oculogyric crisis 12.76 10.90 9 33506 1224 46651323
Gastric banding 12.57 10.90 4 33511 86 46652461
Malignant neoplasm progression 12.48 10.90 17 33498 64909 46587638
Abdominal discomfort 12.41 10.90 61 33454 151104 46501443
Hangover 12.36 10.90 9 33506 1286 46651261
Cerebral artery occlusion 12.35 10.90 8 33507 946 46651601
Diplopia 12.12 10.90 36 33479 19369 46633178
Acute respiratory failure 12.10 10.90 3 33512 29135 46623412
Eating disorder 11.96 10.90 30 33485 14624 46637923
Tongue biting 11.94 10.90 9 33506 1355 46651192
Drug tolerance 11.77 10.90 13 33502 3205 46649342
Grimacing 11.77 10.90 6 33509 451 46652096
Petit mal epilepsy 11.77 10.90 13 33502 3207 46649340
Drug abuser 11.72 10.90 13 33502 3220 46649327
Drug intolerance 11.70 10.90 60 33455 146989 46505558
Drug use disorder 11.69 10.90 12 33503 2723 46649824
Hypoxia 11.64 10.90 12 33503 51826 46600721
Femur fracture 11.64 10.90 6 33509 36991 46615556
Mental disorder 11.62 10.90 39 33476 22386 46630161
Schizoaffective disorder bipolar type 11.57 10.90 4 33511 112 46652435
Horner's syndrome 11.55 10.90 3 33512 30 46652517
Sleep disorder 11.51 10.90 65 33450 46730 46605817
Hallucinations, mixed 11.48 10.90 14 33501 3835 46648712
Treatment noncompliance 11.46 10.90 47 33468 29684 46622863
Hyperacusis 11.45 10.90 10 33505 1854 46650693
Nephrogenic diabetes insipidus 11.38 10.90 7 33508 756 46651791
Radius fracture 11.37 10.90 13 33502 3329 46649218
Tonic convulsion 11.28 10.90 8 33507 1098 46651449
White blood cell count decreased 11.23 10.90 42 33473 112189 46540358
Loss of consciousness 11.23 10.90 123 33392 108115 46544432
Balance disorder 11.17 10.90 82 33433 64439 46588108
Diaphragmalgia 11.07 10.90 4 33511 128 46652419
Infected cyst 10.97 10.90 7 33508 807 46651740
Nervousness 10.96 10.90 45 33470 28430 46624117

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product quality issue 857.48 13.28 429 35732 18345 29897972
No adverse event 637.06 13.28 343 35818 17076 29899241
Aggression 614.33 13.28 440 35721 36467 29879850
Tic 515.43 13.28 161 36000 1871 29914446
Agitation 406.60 13.28 408 35753 53665 29862652
Abnormal behaviour 404.43 13.28 296 35865 25327 29890990
Suicidal ideation 336.76 13.28 307 35854 35807 29880510
Product substitution issue 318.24 13.28 180 35981 9855 29906462
Wrong technique in product usage process 312.49 13.28 276 35885 30879 29885438
Irritability 305.56 13.28 240 35921 22810 29893507
Application site erythema 301.19 13.28 111 36050 2192 29914125
Psychomotor hyperactivity 292.22 13.28 159 36002 8065 29908252
Attention deficit hyperactivity disorder 276.30 13.28 98 36063 1726 29914591
Growth retardation 219.91 13.28 80 36081 1520 29914797
Psychotic disorder 212.44 13.28 189 35972 21326 29894991
Disturbance in attention 209.82 13.28 190 35971 21939 29894378
Dyskinesia 204.14 13.28 186 35975 21648 29894669
Product administration error 199.79 13.28 154 36007 14223 29902094
Product administered at inappropriate site 196.23 13.28 74 36087 1561 29914756
Acute kidney injury 195.01 13.28 46 36115 273796 29642521
Crying 192.48 13.28 106 36055 5503 29910814
Anxiety 179.94 13.28 359 35802 89512 29826805
Application site irritation 165.98 13.28 53 36108 664 29915653
Application site pruritus 163.82 13.28 62 36099 1321 29914996
Dystonia 157.00 13.28 114 36047 9613 29906704
Suicide attempt 150.65 13.28 203 35958 36494 29879823
Tachycardia 146.84 13.28 294 35867 73445 29842872
Pneumonia 146.65 13.28 114 36047 334192 29582125
Incorrect product administration duration 142.55 13.28 77 36084 3845 29912472
Insomnia 142.28 13.28 334 35827 93002 29823315
Death 134.99 13.28 140 36021 357143 29559174
Depression 134.98 13.28 321 35840 90116 29826201
Choreoathetosis 132.76 13.28 48 36113 895 29915422
Educational problem 132.31 13.28 37 36124 282 29916035
Disturbance in social behaviour 128.80 13.28 53 36108 1418 29914899
Impulsive behaviour 126.63 13.28 57 36104 1908 29914409
Anger 126.57 13.28 106 36055 11014 29905303
Intentional product misuse 124.70 13.28 180 35981 34487 29881830
Drug ineffective 116.84 13.28 755 35406 339632 29576685
Hallucination, visual 105.39 13.28 113 36048 16000 29900317
Anaemia 104.29 13.28 61 36100 207931 29708386
Intentional overdose 101.88 13.28 181 35980 41300 29875017
Withdrawal syndrome 97.67 13.28 92 36069 11158 29905159
Trismus 96.03 13.28 50 36111 2315 29914002
Mydriasis 94.61 13.28 70 36091 6073 29910244
Oppositional defiant disorder 94.22 13.28 30 36131 372 29915945
Priapism 91.46 13.28 62 36099 4681 29911636
Palpitations 89.62 13.28 152 36009 33421 29882896
Coronary artery dissection 89.40 13.28 24 36137 154 29916163
Drug diversion 87.04 13.28 35 36126 881 29915436
Product prescribing error 86.72 13.28 104 36057 16629 29899688
Drug dependence 86.12 13.28 117 36044 21178 29895139
Product complaint 84.60 13.28 64 36097 5742 29910575
Diarrhoea 83.80 13.28 174 35987 333929 29582388
Hallucination, auditory 82.97 13.28 79 36082 9710 29906607
Emotional disorder 82.87 13.28 60 36101 5034 29911283
Therapeutic product effect decreased 82.09 13.28 135 36026 28941 29887376
Hallucination, tactile 81.81 13.28 25 36136 268 29916049
Hypotension 80.81 13.28 74 36087 200491 29715826
Somnolence 79.33 13.28 277 35884 96486 29819831
Depressed mood 78.83 13.28 100 36061 16929 29899388
Overdose 78.50 13.28 252 35909 84085 29832232
Hallucination 78.40 13.28 179 35982 48880 29867437
Homicidal ideation 77.55 13.28 44 36117 2419 29913898
Bruxism 76.84 13.28 36 36125 1323 29914994
Dyspnoea 76.66 13.28 182 35979 333113 29583204
Sleep disorder 76.42 13.28 119 36042 24360 29891957
Precocious puberty 75.96 13.28 19 36142 88 29916229
Sepsis 74.64 13.28 42 36119 146353 29769964
Trichotillomania 73.75 13.28 17 36144 51 29916266
Restlessness 70.74 13.28 110 36051 22489 29893828
Application site rash 69.64 13.28 29 36132 800 29915517
Renal failure 68.66 13.28 35 36126 128931 29787386
Febrile neutropenia 68.09 13.28 22 36139 106671 29809646
Gastrointestinal haemorrhage 67.76 13.28 10 36151 83436 29832881
Logorrhoea 67.74 13.28 38 36123 2044 29914273
Paranoia 67.58 13.28 72 36089 10116 29906201
Mood altered 66.93 13.28 65 36096 8185 29908132
Mania 64.84 13.28 67 36094 9087 29907230
Decreased eye contact 64.46 13.28 23 36138 412 29915905
Cardiac failure congestive 62.24 13.28 13 36148 84394 29831923
Affect lability 61.93 13.28 43 36118 3375 29912942
Serotonin syndrome 61.54 13.28 91 36070 17800 29898517
Intentional self-injury 60.33 13.28 78 36083 13454 29902863
Haemoglobin decreased 59.19 13.28 32 36129 114066 29802251
Toxicity to various agents 59.18 13.28 391 35770 176792 29739525
Drug use disorder 59.17 13.28 41 36120 3207 29913110
Euphoric mood 57.49 13.28 45 36116 4245 29912072
Decreased appetite 57.00 13.28 342 35819 149568 29766749
Obsessive-compulsive disorder 56.72 13.28 44 36117 4097 29912220
Renal impairment 56.16 13.28 16 36145 84168 29832149
Apathy 56.08 13.28 52 36109 6180 29910137
Headache 55.94 13.28 394 35767 181912 29734405
Application site pain 55.87 13.28 31 36130 1632 29914685
Product administered to patient of inappropriate age 55.71 13.28 36 36125 2507 29913810
Feeling abnormal 54.97 13.28 172 35989 56584 29859733
Interstitial lung disease 54.36 13.28 5 36156 60192 29856125
Pyrexia 54.13 13.28 179 35982 294310 29622007
General physical health deterioration 53.36 13.28 27 36134 99917 29816400
Speech disorder 52.65 13.28 101 36060 24411 29891906
Thrombocytopenia 51.16 13.28 54 36107 136990 29779327
Autism spectrum disorder 50.91 13.28 27 36134 1298 29915019
Multiple organ dysfunction syndrome 50.63 13.28 8 36153 63479 29852838
Pancytopenia 48.45 13.28 21 36140 85031 29831286
Social avoidant behaviour 47.20 13.28 34 36127 2829 29913488
Formication 46.97 13.28 28 36133 1689 29914628
Blood creatinine increased 46.84 13.28 26 36135 91349 29824968
Enuresis 46.13 13.28 28 36133 1746 29914571
Application site urticaria 45.97 13.28 12 36149 68 29916249
Platelet count decreased 45.29 13.28 37 36124 106092 29810225
Gynaecomastia 45.06 13.28 53 36108 8298 29908019
Oromandibular dystonia 44.99 13.28 18 36143 447 29915870
Keratoconus 44.70 13.28 11 36150 47 29916270
Torticollis 44.43 13.28 23 36138 1052 29915265
Product taste abnormal 43.58 13.28 23 36138 1095 29915222
Respiratory failure 43.05 13.28 35 36126 100607 29815710
Therapeutic response unexpected 42.34 13.28 53 36108 8850 29907467
Product use issue 42.31 13.28 137 36024 45879 29870438
Alice in wonderland syndrome 41.96 13.28 9 36152 17 29916300
Hyperkalaemia 41.41 13.28 14 36147 65996 29850321
Drug abuse 41.12 13.28 202 35959 81870 29834447
Mood swings 40.49 13.28 48 36113 7578 29908739
Neutropenia 40.23 13.28 58 36103 128482 29787835
Dermatillomania 40.10 13.28 9 36152 23 29916294
Raynaud's phenomenon 40.10 13.28 15 36146 309 29916008
Hallucinations, mixed 39.82 13.28 29 36132 2454 29913863
Increased appetite 39.57 13.28 41 36120 5576 29910741
Drug screen negative 39.28 13.28 14 36147 250 29916067
Extrapyramidal disorder 37.65 13.28 55 36106 10638 29905679
Cardiac failure 36.94 13.28 28 36133 83390 29832927
Excessive eye blinking 36.17 13.28 13 36148 238 29916079
Product colour issue 35.61 13.28 15 36146 426 29915891
Product adhesion issue 35.23 13.28 22 36139 1443 29914874
Oedema peripheral 34.87 13.28 46 36115 105786 29810531
Atrial fibrillation 34.61 13.28 48 36113 108076 29808241
Heart rate increased 34.44 13.28 114 36047 38607 29877710
Off label use 34.35 13.28 455 35706 248835 29667482
Ventricular parasystole 34.32 13.28 6 36155 0 29916317
Onychophagia 34.22 13.28 8 36153 26 29916291
Suicidal behaviour 34.14 13.28 21 36140 1341 29914976
Phobia 34.00 13.28 10 36151 93 29916224
Incorrect dose administered 33.44 13.28 99 36062 31587 29884730
Generalised tonic-clonic seizure 33.06 13.28 73 36088 19478 29896839
Septic shock 32.73 13.28 18 36143 63589 29852728
White blood cell count decreased 32.52 13.28 32 36129 83915 29832402
Hypertension 32.43 13.28 254 35907 121100 29795217
Plasma cell myeloma 32.39 13.28 12 36149 53450 29862867
Coordination abnormal 32.39 13.28 42 36119 7263 29909054
Muscle contracture 32.23 13.28 19 36142 1123 29915194
Screaming 32.04 13.28 20 36141 1311 29915006
Affective disorder 32.04 13.28 28 36133 3080 29913237
Sleep apnoea syndrome 32.03 13.28 66 36095 16791 29899526
Drug tolerance 31.86 13.28 24 36137 2138 29914179
Treatment noncompliance 31.66 13.28 84 36077 25169 29891148
Rheumatoid arthritis 31.07 13.28 6 36155 41191 29875126
Tourette's disorder 30.96 13.28 9 36152 80 29916237
Asthenia 30.19 13.28 151 36010 221139 29695178
Peripheral coldness 29.42 13.28 38 36123 6545 29909772
Bipolar disorder 29.23 13.28 29 36132 3747 29912570
Rebound effect 29.13 13.28 20 36141 1541 29914776
Peripheral swelling 29.01 13.28 19 36142 61055 29855262
Tardive dyskinesia 28.80 13.28 33 36128 5024 29911293
Tremor 28.61 13.28 172 35989 75191 29841126
Sympathomimetic effect 28.60 13.28 5 36156 0 29916317
Hyperkinesia 28.10 13.28 22 36139 2076 29914241
Gilbert's syndrome 27.88 13.28 7 36154 33 29916284
Delusion 27.73 13.28 51 36110 11938 29904379
Joint swelling 27.67 13.28 11 36150 46935 29869382
Arthralgia 27.37 13.28 79 36082 135712 29780605
Metabolic acidosis 27.13 13.28 6 36155 37455 29878862
Nervousness 27.08 13.28 50 36111 11738 29904579
Cough 26.88 13.28 71 36090 125571 29790746
Pain 26.37 13.28 113 36048 172528 29743789
Application site erosion 26.24 13.28 8 36153 85 29916232
Melaena 26.05 13.28 4 36157 32433 29883884
Chronic kidney disease 25.57 13.28 7 36154 37831 29878486
Dysphemia 25.36 13.28 18 36143 1463 29914854
International normalised ratio increased 25.30 13.28 13 36148 47726 29868591
Change in sustained attention 25.14 13.28 5 36156 5 29916312
Completed suicide 24.80 13.28 205 35956 99287 29817030
Mental disorder 24.78 13.28 52 36109 13397 29902920
Delayed puberty 24.78 13.28 9 36152 170 29916147
Infection 24.63 13.28 35 36126 78039 29838278
Cataplexy 24.61 13.28 11 36150 362 29915955
Polydipsia psychogenic 24.17 13.28 8 36153 113 29916204
Cerebral congestion 24.13 13.28 6 36155 27 29916290
Multiple cardiac defects 23.62 13.28 7 36154 67 29916250
Somnambulism 23.62 13.28 24 36137 3190 29913127
Pleural effusion 23.57 13.28 33 36128 74033 29842284
Hyperhidrosis 23.50 13.28 150 36011 66940 29849377
Product dispensing error 23.26 13.28 32 36129 5857 29910460
Fall 23.16 13.28 127 36034 181745 29734572
Weight gain poor 23.02 13.28 14 36147 876 29915441
Coronary artery disease 22.89 13.28 16 36145 49696 29866621
Distractibility 22.78 13.28 10 36151 315 29916002
Blood urea increased 22.78 13.28 5 36156 31376 29884941
Oxygen saturation decreased 22.77 13.28 12 36149 43428 29872889
Illusion 22.26 13.28 13 36148 755 29915562
Erythema 22.25 13.28 37 36124 77414 29838903
Malignant neoplasm progression 22.22 13.28 33 36128 72254 29844063
Colitis 22.19 13.28 5 36156 30815 29885502
Dehydration 21.98 13.28 76 36085 123463 29792854
Drug withdrawal syndrome 21.96 13.28 63 36098 19746 29896571
Tongue spasm 21.90 13.28 6 36155 42 29916275
Self-injurious ideation 21.82 13.28 17 36144 1592 29914725
Infusion related reaction 21.57 13.28 11 36150 40553 29875764
Panic attack 21.44 13.28 38 36123 8643 29907674
Hyponatraemia 21.32 13.28 30 36131 67172 29849145
Liver disorder 21.04 13.28 5 36156 29717 29886600
School refusal 21.00 13.28 5 36156 18 29916299
Sudden death 20.92 13.28 53 36108 15439 29900878
Application site dryness 20.88 13.28 6 36155 51 29916266
Substance abuse 20.27 13.28 33 36128 7007 29909310
Petit mal epilepsy 19.98 13.28 20 36141 2611 29913706
Seizure 19.96 13.28 194 35967 98281 29818036
Neuropathy peripheral 19.93 13.28 34 36127 70441 29845876
Application site scab 19.83 13.28 6 36155 62 29916255
Strabismus 19.72 13.28 14 36147 1138 29915179
Performance status decreased 19.52 13.28 24 36137 3933 29912384
Drooling 19.51 13.28 21 36140 2984 29913333
Pain in extremity 19.48 13.28 68 36093 110153 29806164
Abdominal distension 19.40 13.28 16 36145 45693 29870624
Regressive behaviour 19.35 13.28 5 36156 27 29916290
Scoliosis 19.31 13.28 16 36145 1636 29914681
Myocardial infarction 19.31 13.28 82 36079 125543 29790774
Muscle twitching 19.25 13.28 35 36126 8120 29908197
Panic reaction 19.22 13.28 15 36146 1408 29914909
Incorrect route of product administration 18.85 13.28 42 36119 11273 29905044
Disease progression 18.74 13.28 43 36118 79831 29836486
Migraine 18.39 13.28 45 36116 12829 29903488
Chorea 18.08 13.28 13 36148 1078 29915239
Cholestasis 18.06 13.28 4 36157 24946 29891371
Suspiciousness 18.05 13.28 9 36152 380 29915937
Negativism 18.03 13.28 9 36152 381 29915936
Drug reaction with eosinophilia and systemic symptoms 17.93 13.28 6 36155 28482 29887835
Product dose omission issue 17.83 13.28 179 35982 91452 29824865
Insulin resistance 17.58 13.28 10 36151 552 29915765
C-reactive protein increased 17.50 13.28 16 36145 43457 29872860
Hepatic function abnormal 17.41 13.28 15 36146 41930 29874387
Accidental exposure to product 17.36 13.28 38 36123 10077 29906240
Erection increased 17.36 13.28 10 36151 566 29915751
Idiopathic intracranial hypertension 17.32 13.28 10 36151 568 29915749
Parasomnia 17.28 13.28 8 36153 286 29916031
Encopresis 17.25 13.28 5 36156 44 29916273
Blood creatine phosphokinase increased 17.22 13.28 101 36060 43747 29872570
Limb girth decreased 17.16 13.28 3 36158 0 29916317
Adhesive tape use 17.16 13.28 3 36158 0 29916317
Cardiac contusion 17.16 13.28 3 36158 0 29916317
Psychopathic personality 17.16 13.28 3 36158 0 29916317
Testicular failure 17.15 13.28 5 36156 45 29916272
Poor quality product administered 17.13 13.28 15 36146 1654 29914663
Haematoma 17.01 13.28 4 36157 23949 29892368
Accommodation disorder 16.98 13.28 7 36154 188 29916129
Dermo-hypodermitis 16.97 13.28 8 36153 298 29916019
Device difficult to use 16.93 13.28 10 36151 593 29915724
Pneumonitis 16.90 13.28 6 36155 27448 29888869
Weight increased 16.89 13.28 151 36010 74762 29841555
Frustration tolerance decreased 16.88 13.28 16 36145 1954 29914363
Blood thyroid stimulating hormone increased 16.88 13.28 19 36142 2837 29913480
Vision blurred 16.86 13.28 97 36064 41719 29874598
Physical assault 16.85 13.28 13 36148 1200 29915117
Wolff-Parkinson-White syndrome 16.68 13.28 7 36154 197 29916120
Pre-existing condition improved 16.67 13.28 16 36145 1985 29914332
Neutrophil count decreased 16.64 13.28 16 36145 42438 29873879
Mucosal inflammation 16.62 13.28 8 36153 30486 29885831
Rash 16.56 13.28 150 36011 191739 29724578
Constipation 16.55 13.28 75 36086 112831 29803486
Hypocalcaemia 16.36 13.28 3 36158 21373 29894944
Chronic obstructive pulmonary disease 16.28 13.28 19 36142 46107 29870210
Application site ulcer 16.27 13.28 4 36157 17 29916300
Libido increased 16.19 13.28 11 36150 833 29915484
Sedation 16.18 13.28 50 36111 16323 29899994
Lower respiratory tract infection 16.17 13.28 6 36155 26708 29889609
Pericardial effusion 16.11 13.28 3 36158 21141 29895176
Stress cardiomyopathy 16.06 13.28 14 36147 1535 29914782
Application site discolouration 15.99 13.28 7 36154 219 29916098
Ascites 15.96 13.28 12 36149 35909 29880408
Bone marrow failure 15.95 13.28 8 36153 29777 29886540
Accidental exposure to product by child 15.95 13.28 14 36147 1549 29914768
Sydenham's chorea 15.91 13.28 4 36157 19 29916298
Vasospasm 15.84 13.28 8 36153 347 29915970
Acute psychosis 15.63 13.28 15 36146 1861 29914456
Oculogyric crisis 15.42 13.28 13 36148 1362 29914955
Hypokalaemia 15.34 13.28 23 36138 50169 29866148
Disinhibition 15.09 13.28 15 36146 1942 29914375
Anorexia nervosa 15.09 13.28 3 36158 3 29916314
Drug resistance 15.04 13.28 3 36158 20130 29896187
Opisthotonus 14.98 13.28 8 36153 390 29915927
Hypoglycaemia 14.97 13.28 24 36137 50957 29865360
Hepatocellular injury 14.95 13.28 6 36155 25465 29890852
Blood growth hormone decreased 14.85 13.28 4 36157 26 29916291
Eye movement disorder 14.83 13.28 21 36140 3947 29912370
Meningitis staphylococcal 14.77 13.28 5 36156 76 29916241
Urinary tract infection 14.71 13.28 43 36118 73616 29842701
Social anxiety disorder 14.67 13.28 7 36154 268 29916049
Acute respiratory distress syndrome 14.67 13.28 5 36156 23467 29892850
Inappropriate affect 14.66 13.28 9 36152 573 29915744
Productive cough 14.66 13.28 9 36152 29944 29886373
Hypoxia 14.55 13.28 22 36139 47832 29868485
Poor quality sleep 14.52 13.28 29 36132 7212 29909105
Prescribed overdose 14.51 13.28 32 36129 8529 29907788
Psoriasis 14.47 13.28 18 36143 42488 29873829
Amnesia 14.47 13.28 63 36098 24258 29892059
Product residue present 14.45 13.28 17 36144 2661 29913656
Hyperacusis 14.32 13.28 9 36152 597 29915720
Thrombosis 14.26 13.28 18 36143 42213 29874104
Stubbornness 14.24 13.28 4 36157 31 29916286
Ataxia 14.23 13.28 38 36123 11424 29904893
Epiphyses delayed fusion 14.23 13.28 3 36158 5 29916312
Pressure of speech 14.20 13.28 8 36153 434 29915883
Gastrooesophageal reflux disease 14.05 13.28 11 36150 32244 29884073
Defect conduction intraventricular 14 13.28 6 36155 178 29916139
Nightmare 13.96 13.28 39 36122 12037 29904280
Reading disorder 13.94 13.28 7 36154 300 29916017
Pulmonary embolism 13.93 13.28 48 36113 78087 29838230
Dysphoria 13.92 13.28 15 36146 2133 29914184
Electrocardiogram T wave inversion 13.89 13.28 15 36146 2139 29914178
Schizotypal personality disorder 13.87 13.28 3 36158 6 29916311
Personality change 13.84 13.28 22 36139 4578 29911739
Narcolepsy 13.83 13.28 8 36153 456 29915861
Compulsions 13.75 13.28 6 36155 186 29916131
Stomatitis 13.54 13.28 15 36146 37264 29879053
Therapeutic product effect delayed 13.51 13.28 11 36150 1098 29915219
Osteonecrosis of jaw 13.44 13.28 3 36158 18615 29897702
Substance-induced psychotic disorder 13.42 13.28 12 36149 1360 29914957
Urinary incontinence 13.41 13.28 48 36113 16892 29899425
Lung disorder 13.37 13.28 11 36150 31458 29884859
Therapeutic product effect increased 13.35 13.28 9 36152 673 29915644

Pharmacologic Action:

SourceCodeDescription
ATC N06BA04 NERVOUS SYSTEM
PSYCHOANALEPTICS
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Centrally acting sympathomimetics
FDA PE N0000175729 Central Nervous System Stimulation
FDA EPC N0000175739 Central Nervous System Stimulant
MeSH PA D002491 Central Nervous System Agents
MeSH PA D000697 Central Nervous System Stimulants
MeSH PA D015259 Dopamine Agents
MeSH PA D018765 Dopamine Uptake Inhibitors
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
CHEBI has role CHEBI:35337 analeptic drug
CHEBI has role CHEBI:35471 psychopharmaceuticals
CHEBI has role CHEBI:35524 sympathomimetic
CHEBI has role CHEBI:35640 adrenergic uptake inhibitors
CHEBI has role CHEBI:37962 adrenergic neuron agents
CHEBI has role CHEBI:51039 dopamine reuptake inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Narcolepsy indication 60380001 DOID:8986
Attention deficit hyperactivity disorder indication 406506008
Depressive disorder off-label use 35489007
Cognitive Impairment following Traumatic Brain Injury off-label use
Gilles de la Tourette's syndrome contraindication 5158005 DOID:11119
Dependent drug abuse contraindication 6525002
Alcoholism contraindication 7200002
Sinus tachycardia contraindication 11092001
Bipolar disorder contraindication 13746004 DOID:3312
Mood swings contraindication 18963009
Lowered convulsive threshold contraindication 19260006
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Feeling agitated contraindication 24199005
Short bowel syndrome contraindication 26629001 DOID:10605
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Tension contraindication 53489000
Anorexia nervosa contraindication 56882008 DOID:8689
Aggressive behavior contraindication 61372001
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Severe anxiety (panic) contraindication 80583007
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Cardiomyopathy contraindication 85898001 DOID:0050700
Thyrotoxicosis contraindication 90739004 DOID:7997
Blurring of visual image contraindication 111516008
Gastrointestinal obstruction contraindication 126765001
Structural disorder of heart contraindication 128599005
Seizure disorder contraindication 128613002
Liver function tests abnormal contraindication 166603001
Angina pectoris contraindication 194828000
Motor tic disorder contraindication 230337001
Cerebrovascular accident contraindication 230690007
Mania contraindication 231494001
Esophageal dysmotility contraindication 266434009 DOID:9192
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Visual impairment contraindication 397540003
Disorder of coronary artery contraindication 414024009
Myocardial infarction in recovery phase contraindication 418044006
Hypertensive urgency contraindication 443482000
Life-Threatening Cardiac Arrhythmias contraindication
Uncontrolled Epilepsy contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.68 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG JORNULLY PM IRONSHORE PHARMS N209311 Aug. 8, 2018 RX CAPSULE, EXTENDED RELEASE ORAL Aug. 8, 2021 NEW PRODUCT
20MG JORNULLY PM IRONSHORE PHARMS N209311 Aug. 8, 2018 RX CAPSULE, EXTENDED RELEASE ORAL Aug. 8, 2021 NEW PRODUCT
40MG JORNULLY PM IRONSHORE PHARMS N209311 Aug. 8, 2018 RX CAPSULE, EXTENDED RELEASE ORAL Aug. 8, 2021 NEW PRODUCT
60MG JORNULLY PM IRONSHORE PHARMS N209311 Aug. 8, 2018 RX CAPSULE, EXTENDED RELEASE ORAL Aug. 8, 2021 NEW PRODUCT
80MG JORNULLY PM IRONSHORE PHARMS N209311 Aug. 8, 2018 RX CAPSULE, EXTENDED RELEASE ORAL Aug. 8, 2021 NEW PRODUCT
25MG ADHANSIA XR PURDUE PHARMA LP N212038 Feb. 27, 2019 RX CAPSULE, EXTENDED RELEASE ORAL Feb. 27, 2022 NEW PRODUCT
35MG ADHANSIA XR PURDUE PHARMA LP N212038 Feb. 27, 2019 RX CAPSULE, EXTENDED RELEASE ORAL Feb. 27, 2022 NEW PRODUCT
45MG ADHANSIA XR PURDUE PHARMA LP N212038 Feb. 27, 2019 RX CAPSULE, EXTENDED RELEASE ORAL Feb. 27, 2022 NEW PRODUCT
55MG ADHANSIA XR PURDUE PHARMA LP N212038 Feb. 27, 2019 RX CAPSULE, EXTENDED RELEASE ORAL Feb. 27, 2022 NEW PRODUCT
70MG ADHANSIA XR PURDUE PHARMA LP N212038 Feb. 27, 2019 RX CAPSULE, EXTENDED RELEASE ORAL Feb. 27, 2022 NEW PRODUCT
85MG ADHANSIA XR PURDUE PHARMA LP N212038 Feb. 27, 2019 RX CAPSULE, EXTENDED RELEASE ORAL Feb. 27, 2022 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 6.18 CHEMBL CHEMBL
Sodium-dependent dopamine transporter Transporter INHIBITOR Ki 6.96 CHEMBL CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 5.25 PDSP
Alpha-2C adrenergic receptor GPCR Ki 6.07 PDSP
Sodium-dependent serotonin transporter Transporter Ki 4.19 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 5.61 PDSP
Sodium-dependent dopamine transporter Transporter IC50 7.08 CHEMBL

External reference:

IDSource
4019832 VUID
N0000147920 NUI
D01296 KEGG_DRUG
20748-11-2 SECONDARY_CAS_RN
4018198 VANDF
4019832 VANDF
C0939301 UMLSCUI
CHEBI:31836 CHEBI
CHEMBL796 ChEMBL_ID
CHEMBL1722 ChEMBL_ID
D008774 MESH_DESCRIPTOR_UI
DB00422 DRUGBANK_ID
4158 PUBCHEM_CID
7236 IUPHAR_LIGAND_ID
485 INN_ID
207ZZ9QZ49 UNII
203188 RXNORM
1038 MMSL
32827 MMSL
37867 MMSL
5092 MMSL
d00900 MMSL
001540 NDDF
004619 NDDF
18548003 SNOMEDCT_US
373337007 SNOMEDCT_US
42163009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ritalin LA HUMAN PRESCRIPTION DRUG LABEL 1 0078-0370 CAPSULE, EXTENDED RELEASE 20 mg ORAL NDA 31 sections
Ritalin LA HUMAN PRESCRIPTION DRUG LABEL 1 0078-0371 CAPSULE, EXTENDED RELEASE 30 mg ORAL NDA 31 sections
Ritalin LA HUMAN PRESCRIPTION DRUG LABEL 1 0078-0372 CAPSULE, EXTENDED RELEASE 40 mg ORAL NDA 31 sections
Ritalin LA HUMAN PRESCRIPTION DRUG LABEL 1 0078-0424 CAPSULE, EXTENDED RELEASE 10 mg ORAL NDA 31 sections
Ritalin HUMAN PRESCRIPTION DRUG LABEL 1 0078-0439 TABLET 5 mg ORAL NDA 30 sections
Ritalin HUMAN PRESCRIPTION DRUG LABEL 1 0078-0440 TABLET 10 mg ORAL NDA 30 sections
Ritalin HUMAN PRESCRIPTION DRUG LABEL 1 0078-0441 TABLET 20 mg ORAL NDA 30 sections
Methylphenidate Hydrochloride(CD) HUMAN PRESCRIPTION DRUG LABEL 1 0093-5292 CAPSULE, EXTENDED RELEASE 50 mg ORAL ANDA 26 sections
Methylphenidate Hydrochloride(CD) HUMAN PRESCRIPTION DRUG LABEL 1 0093-5293 CAPSULE, EXTENDED RELEASE 60 mg ORAL ANDA 26 sections
Methylphenidate Hydrochloride(CD) HUMAN PRESCRIPTION DRUG LABEL 1 0093-5295 CAPSULE, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Methylphenidate Hydrochloride(CD) HUMAN PRESCRIPTION DRUG LABEL 1 0093-5296 CAPSULE, EXTENDED RELEASE 20 mg ORAL ANDA 26 sections
Methylphenidate Hydrochloride(CD) HUMAN PRESCRIPTION DRUG LABEL 1 0093-5297 CAPSULE, EXTENDED RELEASE 30 mg ORAL ANDA 26 sections
Methylphenidate Hydrochloride(CD) HUMAN PRESCRIPTION DRUG LABEL 1 0093-5298 CAPSULE, EXTENDED RELEASE 40 mg ORAL ANDA 26 sections
Methylphenidate Hydrochloride(LA) HUMAN PRESCRIPTION DRUG LABEL 1 0093-5346 CAPSULE, EXTENDED RELEASE 20 mg ORAL ANDA 29 sections
Methylphenidate Hydrochloride(LA) HUMAN PRESCRIPTION DRUG LABEL 1 0093-5347 CAPSULE, EXTENDED RELEASE 30 mg ORAL ANDA 29 sections
Methylphenidate Hydrochloride(LA) HUMAN PRESCRIPTION DRUG LABEL 1 0093-5348 CAPSULE, EXTENDED RELEASE 40 mg ORAL ANDA 29 sections
Methylphenidate Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1736 CAPSULE, EXTENDED RELEASE 10 mg ORAL ANDA 15 sections
Methylphenidate Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1737 CAPSULE, EXTENDED RELEASE 20 mg ORAL ANDA 15 sections
Methylphenidate Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1738 CAPSULE, EXTENDED RELEASE 30 mg ORAL ANDA 15 sections
Methylphenidate Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1739 CAPSULE, EXTENDED RELEASE 40 mg ORAL ANDA 15 sections
Methylphenidate Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1740 CAPSULE, EXTENDED RELEASE 50 mg ORAL ANDA 15 sections
Methylphenidate Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1741 CAPSULE, EXTENDED RELEASE 60 mg ORAL ANDA 15 sections
METHYLPHENIDATE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0115-1800 TABLET 5 mg ORAL ANDA 28 sections
METHYLPHENIDATE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0115-1801 TABLET 10 mg ORAL ANDA 28 sections
METHYLPHENIDATE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0115-1802 TABLET 20 mg ORAL ANDA 28 sections
Methylphenidate Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0121-0896 SOLUTION 5 mg ORAL ANDA 21 sections
Methylphenidate Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0121-1792 SOLUTION 10 mg ORAL ANDA 21 sections
Methylphenidate Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-8155 TABLET, FILM COATED, EXTENDED RELEASE 18 mg ORAL ANDA 33 sections
Methylphenidate Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-8156 TABLET, FILM COATED, EXTENDED RELEASE 27 mg ORAL ANDA 33 sections
Methylphenidate Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-8157 TABLET, FILM COATED, EXTENDED RELEASE 36 mg ORAL ANDA 33 sections